A Beijing court has ruled against Apple Inc by upholding the validity of a patent held by a Chinese company, clearing the way for the Chinese company to continue its own case against Apple for infringing intellectual property rights.

Apple had taken Shanghai-based Zhizhen Internet Technology and China's State Intellectual Property Office to court to seek a ruling that Zhizhen's patent rights to a speech recognition technology were invalid.

But the Beijing First Intermediate Court on Tuesday decided in Zhizhen's favour, the People's Daily state newspaper reported on Wednesday.

After the verdict, Apple said it intended to take the case to the Beijing Higher People's Court, according to the People's Daily.

"Unfortunately, we were not aware of Zhizhen's patent before we introduced Siri [speech recognition technology] and we do not believe we are using this patent," said a Beijing-based Apple spokeswoman in an emailed statement to Reuters.

"While a separate court considers this question, we remain open to reasonable discussions with Zhizhen," the spokeswoman said.

Zhizhen declined to comment when contacted by Reuters.

Zhizhen sued the U.S. firm in 2012 for intellectual property rights infringement, saying Apple's Siri used on devices including the iPhone violated Zhizhen's own voice system patents.

Related Articles

Qualcomm faces China bribery allegations from U.S. regulator

by Reuters |

Leading mobile chipmaker Qualcomm said on Wednesday it could face a civil action from U.S. authorities over alleged bribery of officials associated with state-owned companies in China.

Marubeni says Chinese authorities detain three staff at grain unit

by Reuters |

Three employees at one of Marubeni Corp's grain trading units in China have been detained by authorities, the Japanese trading house said on Thursday, a move sources told Reuters was prompted by allegations the unit evaded taxes on soy bean imports.

GSK case a 'warning' to all foreign firms in China

by Reuters |

Corruption charges against GlaxoSmithKline Plc executives in China are a warning to other foreign firms and could do irreparable damage to the British drugmaker's Chinese operations, the official Xinhua news agency said on Friday.